Medicamen Biotech Limited Net Assets

Latest as of March 2026: Rs2.76 Billion INR ≈ $29.80 Million USD

Medicamen Biotech Limited net assets. Based on the latest financial reports, Medicamen Biotech Limited (MEDICAMEQ) has net assets worth Rs2.76 Billion INR (≈ $29.80 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs3.72 Billion ≈ $40.23 Million USD) and total liabilities (Rs964.38 Million ≈ $10.43 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Medicamen Biotech Limited annual equity growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs2.76 Billion
% of Total Assets	74.07%
Annual Growth Rate	18.95%
5-Year Change	88.13%
10-Year Change	928.91%
Growth Volatility	38.89

Net Assets of Medicamen Biotech Limited (2006–2026)

Net assets of Medicamen Biotech Limited from 2006 to 2026. This chart illustrates how Medicamen Biotech Limited's net assets have evolved over time, based on quarterly financial data. See Medicamen Biotech Limited balance sheet quality to measure how much of total assets are equity-financed.

Annual Net Assets for Medicamen Biotech Limited (2006–2026)

The table below shows the annual net assets of Medicamen Biotech Limited from 2006 to 2026. For live market cap and overall valuation, see market value of Medicamen Biotech Limited.

Year	Net Assets	Change
2026-03-31	Rs2.76 Billion ≈ $29.80 Million	+29.50%
2025-03-31	Rs2.13 Billion ≈ $23.01 Million	+2.80%
2024-03-31	Rs2.07 Billion ≈ $22.38 Million	+7.02%
2023-03-31	Rs1.93 Billion ≈ $20.92 Million	+32.05%
2022-03-31	Rs1.46 Billion ≈ $15.84 Million	+10.22%
2021-03-31	Rs1.33 Billion ≈ $14.37 Million	+9.63%
2020-03-31	Rs1.21 Billion ≈ $13.11 Million	+39.92%
2019-03-31	Rs866.34 Million ≈ $9.37 Million	+16.12%
2018-03-31	Rs746.08 Million ≈ $8.07 Million	+178.59%
2017-03-31	Rs267.81 Million ≈ $2.90 Million	+49.54%
2016-03-31	Rs179.09 Million ≈ $1.94 Million	+4.21%
2015-03-31	Rs171.85 Million ≈ $1.86 Million	+3.91%
2014-03-31	Rs165.38 Million ≈ $1.79 Million	+5.22%
2013-03-31	Rs157.17 Million ≈ $1.70 Million	-21.81%
2012-03-31	Rs201.01 Million ≈ $2.17 Million	-1.52%
2011-03-31	Rs204.12 Million ≈ $2.21 Million	+25.53%
2010-03-31	Rs162.61 Million ≈ $1.76 Million	+25.47%
2009-03-31	Rs129.60 Million ≈ $1.40 Million	+11.89%
2008-03-31	Rs115.83 Million ≈ $1.25 Million	+14.99%
2007-03-31	Rs100.73 Million ≈ $1.09 Million	+17.58%
2006-03-31	Rs85.67 Million ≈ $926.49K	--

Equity Component Analysis

This analysis shows how different components contribute to Medicamen Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 105218900000.0% over the analyzed period, indicating profitable operations and earnings retention.

Medicamen Biotech Limited Net Assets Breakdown (March 2026)

Medicamen Biotech Limited net assets breakdown by equity component as of March 2026.

Component	Amount	Percentage
Retained Earnings	Rs1.05 Billion	38.19%
Common Stock	Rs135.63 Million	4.92%
Other Comprehensive Income	Rs103.50 Million	3.76%
Other Components	Rs1.46 Billion	53.14%
Total Equity	Rs2.76 Billion	100.00%

Medicamen Biotech Limited Competitors by Market Cap

The table below lists competitors of Medicamen Biotech Limited ranked by their market capitalization.

Company	Market Cap
Rosebank Industries PLC LSE:ROSE	$38.60 Million
MK Trend Co. Ltd. KO:069640	$38.61 Million
Cheil Grinding KO:001560	$38.61 Million
East Asia Holdings Investment Limited KQ:900110	$38.62 Million
Augwind Energy Tech Storage Ltd TA:AUGN	$38.59 Million
Hung Chou Fiber Ind Co Ltd TW:1413	$38.58 Million
FELIX Gold Ltd AU:FXG	$38.54 Million
LAVA THERAP. B.V. EO-12 F:4PKB	$38.54 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medicamen Biotech Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 2,127,809,000 to 2,755,500,000, a change of 627,691,000 (29.5%).
Net income of 96,413,000 contributed positively to equity growth.
Dividend payments of 13,563,000 reduced retained earnings.
New share issuances of 535,679,000 increased equity.
Other comprehensive income increased equity by 86,305,000.
Other factors decreased equity by 77,143,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs96.41 Million	+3.5%
Dividends Paid	Rs13.56 Million	-0.49%
Share Issuances	Rs535.68 Million	+19.44%
Other Comprehensive Income	Rs86.31 Million	+3.13%
Other Changes	Rs-77.14 Million	-2.8%
Total Change	Rs-	29.50%

Book Value vs Market Value Analysis

This analysis compares Medicamen Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.28x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 23.72x to 1.28x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-03-31	Rs11.09	Rs263.15	x
2007-03-31	Rs13.04	Rs263.15	x
2008-03-31	Rs15.04	Rs263.15	x
2009-03-31	Rs16.78	Rs263.15	x
2010-03-31	Rs21.06	Rs263.15	x
2011-03-31	Rs26.42	Rs263.15	x
2012-03-31	Rs25.45	Rs263.15	x
2013-03-31	Rs18.77	Rs263.15	x
2014-03-31	Rs19.48	Rs263.15	x
2015-03-31	Rs19.03	Rs263.15	x
2016-03-31	Rs18.06	Rs263.15	x
2017-03-31	Rs25.69	Rs263.15	x
2018-03-31	Rs66.62	Rs263.15	x
2019-03-31	Rs74.06	Rs263.15	x
2020-03-31	Rs99.22	Rs263.15	x
2021-03-31	Rs108.78	Rs263.15	x
2022-03-31	Rs119.89	Rs263.15	x
2023-03-31	Rs155.28	Rs263.15	x
2024-03-31	Rs163.50	Rs263.15	x
2025-03-31	Rs167.49	Rs263.15	x
2026-03-31	Rs206.34	Rs263.15	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medicamen Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.50%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 4.88%
• Asset Turnover: 0.53x
• Equity Multiplier: 1.35x
Recent ROE (3.50%) is below the historical average (7.68%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	17.44%	2.87%	1.54x	3.95x	Rs6.38 Million
2007	14.95%	2.51%	1.29x	4.61x	Rs4.99 Million
2008	13.04%	1.96%	1.49x	4.47x	Rs3.52 Million
2009	10.63%	1.60%	1.88x	3.53x	Rs812.51K
2010	24.45%	3.91%	1.76x	3.55x	Rs23.50 Million
2011	13.60%	2.26%	1.76x	3.43x	Rs7.36 Million
2012	-4.10%	-0.82%	1.46x	3.43x	Rs-28.35 Million
2013	-31.35%	-7.70%	0.98x	4.15x	Rs-64.99 Million
2014	0.57%	0.13%	1.13x	3.90x	Rs-15.60 Million
2015	2.56%	0.57%	1.13x	4.00x	Rs-12.78 Million
2016	2.69%	0.71%	1.12x	3.35x	Rs-13.10 Million
2017	19.27%	6.26%	1.12x	2.74x	Rs24.82 Million
2018	13.55%	9.07%	0.95x	1.58x	Rs26.52 Million
2019	13.88%	9.81%	0.90x	1.58x	Rs33.62 Million
2020	10.96%	10.59%	0.69x	1.50x	Rs11.70 Million
2021	9.13%	10.76%	0.58x	1.46x	Rs-11.60 Million
2022	10.17%	12.90%	0.51x	1.54x	Rs2.51 Million
2023	7.67%	10.54%	0.51x	1.44x	Rs-44.97 Million
2024	5.28%	6.10%	0.61x	1.42x	Rs-97.67 Million
2025	3.34%	4.37%	0.55x	1.40x	Rs-141.70 Million
2026	3.50%	4.88%	0.53x	1.35x	Rs-179.14 Million

Industry Comparison

This section compares Medicamen Biotech Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $29,969,481,595
Average return on equity (ROE) among peers: 12.70%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Medicamen Biotech Limited (MEDICAMEQ)	Rs2.76 Billion	17.44%	0.35x	$38.60 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$328.12 Million	0.87%	1.65x	$33.51 Million
Aarti Drugs Limited (AARTIDRUGS)	$5.43 Billion	16.52%	1.69x	$449.90 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$13.86 Billion	-0.01%	0.47x	$908.26 Million
Abbott India Limited (ABBOTINDIA)	$26.02 Billion	26.54%	0.48x	$6.23 Billion
Ajanta Pharma Limited (AJANTPHARM)	$11.72 Billion	34.25%	0.26x	$4.48 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$1.24 Billion
Alkem Laboratories Limited (ALKEM)	$63.09 Billion	17.86%	0.58x	$6.75 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$2.16 Billion	28.39%	0.27x	$160.43 Million
Alembic Pharmaceuticals Limited (APLLTD)	$31.90 Billion	25.98%	0.88x	$1.93 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$138.92 Billion	17.02%	0.90x	$10.61 Billion

About Medicamen Biotech Limited

NSE:MEDICAMEQ India Drug Manufacturers - Specialty & Generic

Market Cap

$38.60 Million

Rs3.57 Billion INR

Market Cap Rank

#22646 Global

#1250 in India

Share Price

Rs263.15

Change (1 day)

+0.38%

52-Week Range

Rs219.88 - Rs415.95

All Time High

Rs1195.88